Customized Solutions for Systemic Lupus Erythematosus (SLE) Model Development
Download
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder characterized by loss of self-tolerance, autoantibody production, immune complex deposition, and heterogeneous manifestations ranging from mild cutaneous involvement to severe renal, neurological, and hematological complications.
Protheragen offers a comprehensive, one‑stop solution for SLE preclinical studies, including custom‑tailored animal model development and fully integrated research services spanning diagnostic and therapeutic development, disease modeling, and pharmacokinetic/toxicological evaluations. Supports investigators with flexible, disease‑relevant models and end‑to‑end capabilities to accelerate the translation of novel SLE therapeutics from bench to bedside.
Overview of Systemic Lupus Erythematosus (SLE) Models
Characterizing the loss of immune tolerance and the subsequent production of antinuclear antibodies (ANAs) is central to effective SLE modeling. To mirror the diverse pathology seen in human individuals, ranging from glomerulonephritis to cutaneous lesions, a variety of spontaneous, induced, and genetically engineered murine models are utilized. Each model offers distinct windows into autoantibody dynamics, end‑organ damage progression, and sex‑biased disease expression, allowing investigators to align model selection with specific research questions.
Applications of Systemic Lupus Erythematosus (SLE) Models
SLE models are broadly applied across preclinical discovery and translational research to bridge mechanistic insights with therapeutic outcomes. The following key applications are supported:
Pathogenesis Elucidation
Investigating the cellular and molecular drivers of systemic inflammation to understand how the loss of immune tolerance leads to chronic organ-specific damage in the kidneys and skin.
Target Validation
Confirming the therapeutic potential of modulating specific cytokines or signaling pathways, such as the interferon signature or B-cell activating factors, within a complex in vivo environment.
Efficacy Testing
Assessing the ability of novel compounds to reduce pathogenic autoantibody titers, lower proteinuria levels, and ameliorate histological tissue pathology to support regulatory submissions.
Biomarker Discovery
Identifying early indicators of disease progression or therapy response through longitudinal sampling facilitates the development of companion diagnostics for better disease stratification.
Workflow for Systemic Lupus Erythematosus (SLE) Model Development
- Consultation and Model Selection: Collaborating with researchers to define the research hypothesis, desired disease phenotype (e.g., renal, cutaneous, neuropsychiatric), species/strain preferences, and time course requirements.
- Model Generation: Generating spontaneous, inducible, or humanized SLE models using validated protocols. For inducible models (e.g., pristane injection, adoptive transfer), precise dosing and timing are executed.
- Baseline Characterization: Establishing historical control data for each model, including body weight, proteinuria scores, anti‑dsDNA titers, complement levels, and hematological parameters at defined ages or post‑induction time points.
- Validation of Disease Phenotype: Performing histopathological examination (e.g., glomerular immune complex deposition, interstitial nephritis, vasculitis), flow cytometry for immune cell subsets, and cytokine/chemokine profiling.
- Customization and Pilot Studies: Introducing genetic modifications, dietary or environmental triggers, or co‑morbidities (e.g., atherosclerosis, osteoporosis) as needed. Conducting pilot studies to confirm reproducibility and effect sizes.
- Scale‑up and Full Study Execution: Generating cohorts of sufficient size for statistical power, with randomized group allocation, blinded assessments, and predefined endpoints.
- Data Delivery and Reporting: Providing raw data, processed analyses, histology slides, and a comprehensive study report compliant with preclinical regulatory standards.
Integrated Preclinical Research Services for Systemic Lupus Erythematosus (SLE)
Beyond model development, a seamless suite of preclinical research services enables holistic evaluation of SLE diagnostics, therapeutics, and disease biology. All services are conducted under strict quality control and can be combined or customized to match specific program needs.
Engineering and validating sensitive assays for autoantibody detection and novel proteomic biomarkers to enhance early-stage disease identification.
In vivo efficacy screening of lead candidates in SLE models, including dose‑finding, route‑of‑administration optimization, and combination therapy studies.
Providing tailored model engineering, including precision genome engineering, humanized immune system mice, and a range of in vitro models, to better capture human‑specific drug responses and disease mechanisms.
Executing rigorous PK, toxicology, biodistribution, and safety pharmacology studies to determine optimal dosing regimens and identify potential off-target effects within an autoimmune context.
Case Study 01-MRL/lpr Mouse Model
The MRL/lpr mouse model carries a spontaneous loss‑of‑function mutation in the Fas gene, leading to defective lymphocyte apoptosis and progressive autoimmune pathology that includes both lupus nephritis and rheumatoid arthritis‑like joint manifestations. To evaluate disease progression and therapeutic intervention, clinical scores (assessing lymphadenopathy and skin ulcerations) were recorded weekly, and renal function was monitored via urinary protein levels and histopathological scoring of lupus nephritis. A parallel cohort received corticosteroid therapy.
Fig.1 Clinical scores (assessing lymphadenopathy and skin ulcerations) were recorded weekly in MRL/lpr mice. Data are presented as mean ± SEM (n=5).
Clinical scores increased with age in vehicle‑treated animals, while corticosteroid therapy significantly reduced disease severity. Severe proteinuria developed by 12 weeks of age in the vehicle group, accompanied by high nephritis activity scores on renal histology. In contrast, drug‑treated mice maintained substantially lower proteinuria levels and markedly reduced histopathological scores.
Fig.2 Urinary protein levels (A) and renal lupus nephritis histopathological scores (B) in MRL/lpr mice. Data are presented as mean ± SEM (n=5; ***p < 0.001, **p < 0.01).
Case Study 02-NZB/WF1 Mouse Model
The NZB/WF1 mouse model is an F1 hybrid derived from New Zealand Black and New Zealand White strains, exhibiting a strong female sex bias and spontaneous development of immune complex‑mediated glomerulonephritis that closely resembles human lupus nephritis. Clinical scores assessing lymphadenopathy and skin ulcerations were recorded weekly and increased with age, with female mice showing more severe phenotypes than males. Disease progression was further quantified by measuring urinary protein concentrations at defined time points and serum anti‑dsDNA antibody levels at the study endpoint.
Fig.3 Clinical scores (assessing lymphadenopathy and skin ulcerations) were recorded weekly in NZB/WF1 mice. Scores increased progressively with age, reflecting disease exacerbation in this spontaneous model. Data are presented as mean ± SEM (n=5).
Urinary protein levels rose progressively over time, with marked elevation observed at 6 weeks and 12 weeks after the onset of proteinuria. Endpoint serum anti‑dsDNA antibody levels, measured by ELISA, were substantially elevated compared to baseline, confirming active autoimmunity and renal involvement.
Fig.4 Urinary protein levels and serum anti‑dsDNA antibody levels in NZB/WF1 mice. Data are presented as mean ± SEM (n=5; **p < 0.01, *p < 0.05).
Case Study 03-Pristane‑induced SLE Model
The pristane‑induced SLE model was established in female BALB/c mice via a single intraperitoneal injection of pristane (2,6,10,14‑tetramethylpentadecane). Pristane administration triggered a lupus‑like autoimmune response, including robust production of multiple autoantibodies (anti‑dsDNA, anti‑Sm, anti‑RNP), sustained type I interferon production, and immune complex‑mediated glomerulonephritis. Pristane‑treated mice were compared to vehicle‑treated controls. Urinary protein levels and serum anti‑dsDNA IgG titers were assessed over time. Pristane‑induced mice showed significantly elevated proteinuria compared to vehicle controls, indicating progressive renal injury. Serum anti‑dsDNA IgG levels, measured by ELISA, were markedly increased in pristane‑treated animals, demonstrating spontaneous autoantibody production consistent with active SLE. This model also recapitulated arthritis‑like features in a subset of animals, supporting its utility for studying both systemic and joint manifestations of lupus.
Fig.5 Urinary protein levels and serum anti‑dsDNA IgG levels in pristane‑induced BALB/c mice. Data are presented as mean ± SEM (n=5; **p < 0.01).
Why Choose Us?
- Deep Domain Expertise: Leveraging years of specialized experience in immunology to provide nuanced data interpretation and strategic study design.
- Broad Model Portfolio: A comprehensive panel of validated in vitro and in vivo models is routinely deployed to cover diverse disease pathways, phenotypes, and therapeutic targets.
- Advanced Technology: Employing advanced platforms such as multi-color flow cytometry, digital pathology, and multiplex cytokine profiling for deep phenotypic insights.
- One‑Stop Service: Seamless integration across all stages, from initial project consultation and model generation through full characterization, study execution, and final data delivery.
Contact Us
Protheragen provides a complete, integrated solution for SLE preclinical research, from custom animal model development to therapeutic efficacy testing and safety pharmacology. Every service is delivered with scientific rigor, translational relevance, and flexible adaptation to specific program objectives. For additional information, study quotes, or to discuss a customized SLE research plan, please contact our scientific team.
Resource Download Request
Please complete the form to download the requested resources.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
- CAR-T Cell Therapy Development Service for Multiple Myeloma (MM)
- Rare Diseases Drug Discovery & Development
- Skin-on-a-Chip Model for Rare Skin Disease
- Your Trusted Partner in Rare Disease Drug Discovery and Development
- Customized Solutions for Hair-Bearing Skin Organoid Model Development
- Customized Solutions for Bronchiolitis Obliterans Syndrome Drug Discovery and Development
- Pulmonary Arterial Hypertension (PAH) Animal Model Service
- Customized Solutions for Food Allergy Animal Model
- Customized Solutions for Systemic Sclerosis (SSc) Animal Model Development
- Customized Solutions for Systemic Lupus Erythematosus (SLE) Model Development
- ImmuCell
- MitoClear
- Customized Solutions for Ankylosing Spondylitis Model Development and Preclinical Research
- Customized Preclinical Solutions for Eosinophilic Esophagitis (EoE) Model Development and Drug Research
- Preclinical Research Services for Primary Biliary Cholangitis (PBC) and Cholestatic Liver Disease Models